Equity Overview
Price & Market Data
Price: $3.50
Daily Change: -$0.138 / 3.95%
Range: $3.25 - $3.65
Market Cap: $2,578,245
Volume: 14,245
Performance Metrics
1 Week: 8.33%
1 Month: 5.72%
3 Months: -17.41%
6 Months: -60.29%
1 Year: -77.71%
YTD: -16.63%
Company Details
Employees: 4
Sector: Health technology
Industry: Pharmaceuticals: other
Country: United States
Details
Qualigen Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of treatments for adult and pediatric cancer in the United States. The company's lead program is QN-302, an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor, which is in Phase 1a clinical trial for the treatment of pancreatic cancer and other solid tumors. It is also developing Pan-RAS that is in preclinical stage for the treatment of advanced solid tumors. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.